Novel Oxindole Sulfonamides and Sulfamides: EPZ031686, the First Orally Bioavailable Small Molecule SMYD3 Inhibitor

[Image: see text] SMYD3 has been implicated in a range of cancers; however, until now no potent selective small molecule inhibitors have been available for target validation studies. A novel oxindole series of SMYD3 inhibitors was identified through screening of the Epizyme proprietary histone methy...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:ACS Med Chem Lett
المؤلفون الرئيسيون: Mitchell, Lorna H., Boriack-Sjodin, P. Ann, Smith, Sherri, Thomenius, Michael, Rioux, Nathalie, Munchhof, Michael, Mills, James E., Klaus, Christine, Totman, Jennifer, Riera, Thomas V., Raimondi, Alejandra, Jacques, Suzanne L., West, Kip, Foley, Megan, Waters, Nigel J., Kuntz, Kevin W., Wigle, Tim J., Scott, Margaret Porter, Copeland, Robert A., Smith, Jesse J., Chesworth, Richard
التنسيق: Artigo
اللغة:Inglês
منشور في: American Chemical Society 2015
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC4753551/
https://ncbi.nlm.nih.gov/pubmed/26985287
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acsmedchemlett.5b00272
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة